---
layout: default
title: Alpha Lipoic Acid Apiole Arnica Montana Whole Cinn
parent: 僅模型預測 (L5)
nav_order: 263
evidence_level: L5
indication_count: 0
---

# Alpha Lipoic Acid Apiole Arnica Montana Whole Cinn
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# 18-Component Botanical/Homeopathic Complex: TxGNN Evaluation Not Available

## One-Sentence Summary

This candidate is a heterogeneous 18-ingredient formulation—comprising botanical extracts (Arnica Montana, Thuja Occidentalis, Sanguinaria Canadensis), animal-derived components (Sus Scrofa Cartilage, Placenta, Umbilical Cord), antioxidants (Alpha Lipoic Acid), and coenzymes (NADIDE, Pantothenic Acid)—with no registered original indication in the US market.
The TxGNN model generated **no repurposing predictions** for this formulation, most likely because the multi-ingredient composition could not be resolved to a single DrugBank entry or knowledge graph node.
Without a mappable pharmacological entity and a prediction target, no evidence-based repurposing evaluation can be conducted at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None recorded |
| Predicted New Indication | None — no TxGNN predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — evaluation not possible |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

The TxGNN pipeline depends on mapping a drug's INN to a single DrugBank node in the knowledge graph. This formulation presents three structural barriers:

**1. No unified DrugBank ID.** The 18 ingredients span botanical extracts, homeopathic dilutions, animal tissues, inorganic minerals, and metabolic cofactors. No single DrugBank identifier covers the combination, so the KG traversal step has no entry point.

**2. No original indication to anchor the query.** TxGNN evaluates *new* disease links by comparing them against known disease edges. With zero approved indications on record, there is no baseline disease context from which to compute a repurposing score.

**3. Multi-ingredient homeopathic pattern.** Several ingredients (Arnica Montana, Thuja Occidentalis, Toxicodendron Pubescens, Solanum Dulcamara, Sanguinaria Canadensis, Sulfur) are classical homeopathic materials typically used in ultra-dilute form. These do not have pharmacokinetic or target-binding data in DrugBank, making mechanistic knowledge graph edges unavailable.

Until the formulation is decomposed into individual pharmacologically active components—each evaluated separately—the TxGNN pipeline cannot produce a meaningful prediction.

---

## Safety Considerations

No formal DDI data or package insert warnings were retrieved. However, several individual components carry known safety signals that warrant disclosure:

- **Comfrey Root** (*Symphytum officinale*): Contains hepatotoxic pyrrolizidine alkaloids. The US FDA has issued warnings against oral use; long-term exposure carries risk of veno-occlusive liver disease.
- **Sanguinaria Canadensis Root**: Contains sanguinarine, linked to leukoplakia and oral mucosal damage in prior oral-care product incidents.
- **Toxicodendron Pubescens Leaf** (poison oak relative): A potent contact allergen; systemic sensitisation is possible even at homeopathic dilutions in susceptible individuals.
- **Apiole** (parsley apiol): Toxic in non-trivial doses; historically associated with abortifacient toxicity.
- **Sus Scrofa Placenta / Umbilical Cord**: Animal-derived biologics require sterility verification and carry theoretical prion/zoonotic transmission risk if not properly processed.

Please obtain and review the full product package insert and conduct ingredient-level safety assessments before any clinical use or further development.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The standard TxGNN drug repurposing pipeline requires a single mappable drug entity with at least one known indication. This 18-component formulation satisfies neither requirement, and the model produced no predictions. Proceeding without a clearly defined active pharmaceutical ingredient and a regulatory anchor would yield unreliable or uninterpretable results.

**To proceed, the following is needed:**

- **Decompose and prioritize components**: Identify the primary pharmacologically active ingredient(s) (strong candidates: Alpha Lipoic Acid, NADIDE, Pantothenic Acid) and run each through TxGNN individually.
- **Obtain DrugBank IDs**: Query DrugBank for each bioactive component separately; retrieve MOA and disease association data.
- **Clarify therapeutic intent**: Determine the intended original indication for the overall formulation (e.g., anti-aging, metabolic support, rheumatic conditions) to provide a baseline disease context.
- **Regulatory status check**: Investigate whether this product—or any single-ingredient derivative—holds approval in any jurisdiction (FDA, EMA, Health Canada).
- **Ingredient-level safety review**: Conduct formal safety assessments for Comfrey Root, Sanguinaria Canadensis, Toxicodendron Pubescens, and Apiole before any further development steps.
- **Re-run pipeline**: After DrugBank IDs and at least one confirmed indication are available for the lead component(s), re-submit to the TxGNN pipeline for a valid repurposing evaluation.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

